| 1 |
Yu Y, Raka F, Adeli K. The Role of the Gut Microbiota in Lipid and Lipoprotein Metabolism. J Clin Med 2019;8:E2227. [PMID: 31861086 DOI: 10.3390/jcm8122227] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 2 |
Hullar MAJ, Jenkins IC, Randolph TW, Curtis KR, Monroe KR, Ernst T, Shepherd JA, Stram DO, Cheng I, Kristal BS, Wilkens LR, Franke A, Le Marchand L, Lim U, Lampe JW. Associations of the gut microbiome with hepatic adiposity in the Multiethnic Cohort Adiposity Phenotype Study. Gut Microbes 2021;13:1965463. [PMID: 34491886 DOI: 10.1080/19490976.2021.1965463] [Reference Citation Analysis]
|
| 3 |
Albhaisi S, Sanyal AJ. Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis. Front Endocrinol (Lausanne) 2021;12:665987. [PMID: 34040583 DOI: 10.3389/fendo.2021.665987] [Reference Citation Analysis]
|
| 4 |
Han H, Jiang Y, Wang M, Melaku M, Liu L, Zhao Y, Everaert N, Yi B, Zhang H. Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis. Crit Rev Food Sci Nutr 2021;:1-18. [PMID: 34404276 DOI: 10.1080/10408398.2021.1966738] [Reference Citation Analysis]
|
| 5 |
Tilg H, Burcelin R, Tremaroli V. Liver tissue microbiome in NAFLD: next step in understanding the gut-liver axis? Gut 2020;69:1373-4. [PMID: 32060128 DOI: 10.1136/gutjnl-2019-320490] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 6 |
Jiao N, Loomba R, Yang ZH, Wu D, Fang S, Bettencourt R, Lan P, Zhu R, Zhu L. Alterations in bile acid metabolizing gut microbiota and specific bile acid genes as a precision medicine to subclassify NAFLD. Physiol Genomics 2021;53:336-48. [PMID: 34151600 DOI: 10.1152/physiolgenomics.00011.2021] [Reference Citation Analysis]
|
| 7 |
Nalpas N, Hoyles L, Anselm V, Ganief T, Martinez-Gili L, Grau C, Droste-Borel I, Davidovic L, Altafaj X, Dumas ME, Macek B. An integrated workflow for enhanced taxonomic and functional coverage of the mouse fecal metaproteome. Gut Microbes 2021;13:1994836. [PMID: 34763597 DOI: 10.1080/19490976.2021.1994836] [Reference Citation Analysis]
|
| 8 |
Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol 2021;19:55-71. [PMID: 32887946 DOI: 10.1038/s41579-020-0433-9] [Cited by in Crossref: 125] [Cited by in F6Publishing: 117] [Article Influence: 62.5] [Reference Citation Analysis]
|
| 9 |
Koopman N, Molinaro A, Nieuwdorp M, Holleboom AG. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2019;50:628-639. [PMID: 31373710 DOI: 10.1111/apt.15416] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 10 |
Jang HR, Lee HY. Mechanisms linking gut microbial metabolites to insulin resistance. World J Diabetes 2021; 12(6): 730-744 [PMID: 34168724 DOI: 10.4239/wjd.v12.i6.730] [Reference Citation Analysis]
|
| 11 |
Delzenne NM, Bindels LB. Microbiome metabolomics reveals new drivers of human liver steatosis. Nat Med 2018;24:906-7. [PMID: 29988145 DOI: 10.1038/s41591-018-0126-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 12 |
Ji L, Li Q, He Y, Zhang X, Zhou Z, Gao Y, Fang M, Yu Z, Rodrigues RM, Gao Y, Li M. Therapeutic potential of traditional Chinese medicine for the treatment of NAFLD: a promising drug Potentilla discolor Bunge. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.05.001] [Reference Citation Analysis]
|
| 13 |
Caussy C, Tripathi A, Humphrey G, Bassirian S, Singh S, Faulkner C, Bettencourt R, Rizo E, Richards L, Xu ZZ, Downes MR, Evans RM, Brenner DA, Sirlin CB, Knight R, Loomba R. A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. Nat Commun 2019;10:1406. [PMID: 30926798 DOI: 10.1038/s41467-019-09455-9] [Cited by in Crossref: 84] [Cited by in F6Publishing: 84] [Article Influence: 28.0] [Reference Citation Analysis]
|
| 14 |
Barretto SA, Lasserre F, Huillet M, Régnier M, Polizzi A, Lippi Y, Fougerat A, Person E, Bruel S, Bétoulières C, Naylies C, Lukowicz C, Smati S, Guzylack L, Olier M, Théodorou V, Mselli-Lakhal L, Zalko D, Wahli W, Loiseau N, Gamet-Payrastre L, Guillou H, Ellero-Simatos S. The pregnane X receptor drives sexually dimorphic hepatic changes in lipid and xenobiotic metabolism in response to gut microbiota in mice. Microbiome 2021;9:93. [PMID: 33879258 DOI: 10.1186/s40168-021-01050-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Shama S, Liu W. Omega-3 Fatty Acids and Gut Microbiota: A Reciprocal Interaction in Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2020;65:906-10. [PMID: 32036510 DOI: 10.1007/s10620-020-06117-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 16 |
Liu KH, Owens JA, Saeedi B, Cohen CE, Bellissimo MP, Naudin C, Darby T, Druzak S, Maner-Smith K, Orr M, Hu X, Fernandes J, Camacho MC, Hunter-Chang S, VanInsberghe D, Ma C, Ganesh T, Yeligar SM, Uppal K, Go YM, Alvarez JA, Vos MB, Ziegler TR, Woodworth MH, Kraft CS, Jones RM, Ortlund E, Neish AS, Jones DP. Microbial metabolite delta-valerobetaine is a diet-dependent obesogen. Nat Metab 2021;3:1694-705. [PMID: 34931082 DOI: 10.1038/s42255-021-00502-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 17 |
Schoeler M, Caesar R. Dietary lipids, gut microbiota and lipid metabolism. Rev Endocr Metab Disord. 2019;20:461-472. [PMID: 31707624 DOI: 10.1007/s11154-019-09512-0] [Cited by in Crossref: 99] [Cited by in F6Publishing: 92] [Article Influence: 49.5] [Reference Citation Analysis]
|
| 18 |
Mesnage R, Antoniou MN, Tsoukalas D, Goulielmos GN, Tsatsakis A. Gut microbiome metagenomics to understand how xenobiotics impact human health. Current Opinion in Toxicology 2018;11-12:51-8. [DOI: 10.1016/j.cotox.2019.02.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 19 |
Delzenne NM, Knudsen C, Beaumont M, Rodriguez J, Neyrinck AM, Bindels LB. Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut–liver axis. Proc Nutr Soc 2019;78:319-28. [DOI: 10.1017/s0029665118002756] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 11.7] [Reference Citation Analysis]
|
| 20 |
Portincasa P, Bonfrate L, Khalil M, Angelis MD, Calabrese FM, D’amato M, Wang DQ, Di Ciaula A. Intestinal Barrier and Permeability in Health, Obesity and NAFLD. Biomedicines 2022;10:83. [DOI: 10.3390/biomedicines10010083] [Reference Citation Analysis]
|
| 21 |
Gao B, Chi L, Zhu Y, Shi X, Tu P, Li B, Yin J, Gao N, Shen W, Schnabl B. An Introduction to Next Generation Sequencing Bioinformatic Analysis in Gut Microbiome Studies. Biomolecules 2021;11:530. [PMID: 33918473 DOI: 10.3390/biom11040530] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 22 |
Yoo T, Joo SK, Kim HJ, Kim HY, Sim H, Lee J, Kim HH, Jung S, Lee Y, Jamialahmadi O, Romeo S, Jeong WI, Hwang GS, Kang KW, Kim JW, Kim W, Choi M; Innovative Target Exploration of NAFLD (ITEN) consortium. Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease. J Hepatol 2021;75:514-23. [PMID: 33892010 DOI: 10.1016/j.jhep.2021.04.011] [Reference Citation Analysis]
|
| 23 |
Agus A, Clément K, Sokol H. Gut microbiota-derived metabolites as central regulators in metabolic disorders. Gut 2021;70:1174-82. [PMID: 33272977 DOI: 10.1136/gutjnl-2020-323071] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 13.5] [Reference Citation Analysis]
|
| 24 |
Yamazaki K, Kato T, Tsuboi Y, Miyauchi E, Suda W, Sato K, Nakajima M, Yokoji-Takeuchi M, Yamada-Hara M, Tsuzuno T, Matsugishi A, Takahashi N, Tabeta K, Miura N, Okuda S, Kikuchi J, Ohno H, Yamazaki K. Oral Pathobiont-Induced Changes in Gut Microbiota Aggravate the Pathology of Nonalcoholic Fatty Liver Disease in Mice. Front Immunol 2021;12:766170. [PMID: 34707622 DOI: 10.3389/fimmu.2021.766170] [Reference Citation Analysis]
|
| 25 |
Sharma SP, Suk KT, Kim DJ. Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases. World J Gastroenterol 2021; 27(37): 6161-6179 [PMID: 34712025 DOI: 10.3748/wjg.v27.i37.6161] [Reference Citation Analysis]
|
| 26 |
Beyoğlu D, Idle JR. Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy. Metabolites 2020;10:E50. [PMID: 32012846 DOI: 10.3390/metabo10020050] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 27 |
Kappel BA, Federici M. Gut microbiome and cardiometabolic risk. Rev Endocr Metab Disord 2019;20:399-406. [DOI: 10.1007/s11154-019-09533-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 28 |
Roager HM, Dragsted LO. Diet‐derived microbial metabolites in health and disease. Nutr Bull 2019;44:216-27. [DOI: 10.1111/nbu.12396] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 29 |
Yu X, Chen X, Wang Z. Characterizing the Personalized Microbiota Dynamics for Disease Classification by Individual-Specific Edge-Network Analysis. Front Genet 2019;10:283. [PMID: 31031795 DOI: 10.3389/fgene.2019.00283] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 30 |
Mayneris-Perxachs J, Puig J, Burcelin R, Dumas ME, Barton RH, Hoyles L, Federici M, Fernández-Real JM. The APOA1bp-SREBF-NOTCH axis is associated with reduced atherosclerosis risk in morbidly obese patients. Clin Nutr 2020;39:3408-18. [PMID: 32199697 DOI: 10.1016/j.clnu.2020.02.034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 31 |
Pell LG, Horne RG, Huntley S, Rahman H, Kar S, Islam MS, Evans KC, Saha SK, Campigotto A, Morris SK, Roth DE, Sherman PM. Antimicrobial susceptibilities and comparative whole genome analysis of two isolates of the probiotic bacterium Lactiplantibacillus plantarum, strain ATCC 202195. Sci Rep 2021;11:15893. [PMID: 34354117 DOI: 10.1038/s41598-021-94997-6] [Reference Citation Analysis]
|
| 32 |
Witjes JJ, Smits LP, Pekmez CT, Prodan A, Meijnikman AS, Troelstra MA, Bouter KEC, Herrema H, Levin E, Holleboom AG, Winkelmeijer M, Beuers UH, van Lienden K, Aron-Wisnewky J, Mannisto V, Bergman JJ, Runge JH, Nederveen AJ, Dragsted LO, Konstanti P, Zoetendal EG, de Vos W, Verheij J, Groen AK, Nieuwdorp M. Donor Fecal Microbiota Transplantation Alters Gut Microbiota and Metabolites in Obese Individuals With Steatohepatitis. Hepatol Commun 2020;4:1578-90. [PMID: 33163830 DOI: 10.1002/hep4.1601] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 33 |
Kartal E, Schmidt TSB, Molina-Montes E, Rodríguez-Perales S, Wirbel J, Maistrenko OM, Akanni WA, Alashkar Alhamwe B, Alves RJ, Carrato A, Erasmus HP, Estudillo L, Finkelmeier F, Fullam A, Glazek AM, Gómez-Rubio P, Hercog R, Jung F, Kandels S, Kersting S, Langheinrich M, Márquez M, Molero X, Orakov A, Van Rossum T, Torres-Ruiz R, Telzerow A, Zych K, Benes V, Zeller G, Trebicka J, Real FX, Malats N, Bork P; MAGIC Study investigators., PanGenEU Study investigators. A faecal microbiota signature with high specificity for pancreatic cancer. Gut 2022:gutjnl-2021-324755. [PMID: 35260444 DOI: 10.1136/gutjnl-2021-324755] [Reference Citation Analysis]
|
| 34 |
Lu D, Huang Y, Kong Y, Tao T, Zhu X. Gut microecology: Why our microbes could be key to our health. Biomed Pharmacother 2020;131:110784. [PMID: 33152942 DOI: 10.1016/j.biopha.2020.110784] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 35 |
Chen L, Kan J, Zheng N, Li B, Hong Y, Yan J, Tao X, Wu G, Ma J, Zhu W, Sheng L, Chen L, Li B, Zhong J, Du J, Li H. A botanical dietary supplement from white peony and licorice attenuates nonalcoholic fatty liver disease by modulating gut microbiota and reducing inflammation. Phytomedicine 2021;91:153693. [PMID: 34403877 DOI: 10.1016/j.phymed.2021.153693] [Reference Citation Analysis]
|
| 36 |
Chen R, Wang J, Zhan R, Zhang L, Wang X. Fecal metabonomics combined with 16S rRNA gene sequencing to analyze the changes of gut microbiota in rats with kidney-yang deficiency syndrome and the intervention effect of You-gui pill. J Ethnopharmacol 2019;244:112139. [PMID: 31401318 DOI: 10.1016/j.jep.2019.112139] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 37 |
Mazzini FN, Cook F, Gounarides J, Marciano S, Haddad L, Tamaroff AJ, Casciato P, Narvaez A, Mascardi MF, Anders M, Orozco F, Quiróz N, Risk M, Gutt S, Gadano A, Méndez García C, Marro ML, Penas-Steinhardt A, Trinks J. Plasma and stool metabolomics to identify microbiota derived-biomarkers of metabolic dysfunction-associated fatty liver disease: effect of PNPLA3 genotype. Metabolomics 2021;17:58. [PMID: 34137937 DOI: 10.1007/s11306-021-01810-6] [Reference Citation Analysis]
|
| 38 |
Jing Y, Yuan Y, Monson M, Wang P, Mu F, Zhang Q, Na W, Zhang K, Wang Y, Leng L, Li Y, Luan P, Wang N, Guo R, Lamont SJ, Li H, Yuan H. Multi-Omics Association Reveals the Effects of Intestinal Microbiome–Host Interactions on Fat Deposition in Broilers. Front Microbiol 2022;12:815538. [DOI: 10.3389/fmicb.2021.815538] [Reference Citation Analysis]
|
| 39 |
Cebola I. Liver gene regulatory networks: Contributing factors to nonalcoholic fatty liver disease. Wiley Interdiscip Rev Syst Biol Med 2020;12:e1480. [PMID: 32020788 DOI: 10.1002/wsbm.1480] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 40 |
Hundertmark J, Krenkel O, Tacke F. Adapted Immune Responses of Myeloid-Derived Cells in Fatty Liver Disease. Front Immunol 2018;9:2418. [PMID: 30405618 DOI: 10.3389/fimmu.2018.02418] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 41 |
Knudsen C, Neyrinck AM, Lanthier N, Delzenne NM. Microbiota and nonalcoholic fatty liver disease: promising prospects for clinical interventions? Curr Opin Clin Nutr Metab Care 2019;22:393-400. [PMID: 31219825 DOI: 10.1097/MCO.0000000000000584] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 42 |
Xu JY, Liu MT, Tao T, Zhu X, Fei FQ. The role of gut microbiota in tumorigenesis and treatment. Biomed Pharmacother 2021;138:111444. [PMID: 33662679 DOI: 10.1016/j.biopha.2021.111444] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 43 |
Sharpton SR, Ajmera V, Loomba R. Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function. Clin Gastroenterol Hepatol 2019;17:296-306. [PMID: 30196156 DOI: 10.1016/j.cgh.2018.08.065] [Cited by in Crossref: 62] [Cited by in F6Publishing: 51] [Article Influence: 15.5] [Reference Citation Analysis]
|
| 44 |
Verdugo-Meza A, Ye J, Dadlani H, Ghosh S, Gibson DL. Connecting the Dots Between Inflammatory Bowel Disease and Metabolic Syndrome: A Focus on Gut-Derived Metabolites. Nutrients 2020;12:E1434. [PMID: 32429195 DOI: 10.3390/nu12051434] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 45 |
[DOI: 10.1101/2021.03.22.436368] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 46 |
Eslam M, George J. Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nat Rev Gastroenterol Hepatol. 2020;17:40-52. [PMID: 31641249 DOI: 10.1038/s41575-019-0212-0] [Cited by in Crossref: 68] [Cited by in F6Publishing: 67] [Article Influence: 22.7] [Reference Citation Analysis]
|
| 47 |
Stachulski AV, Knausenberger TB, Shah SN, Hoyles L, McArthur S. A host-gut microbial amino acid co-metabolite, p-cresol glucuronide, promotes blood-brain barrier integrity in vivo. Tissue Barriers 2022;:2073175. [PMID: 35596559 DOI: 10.1080/21688370.2022.2073175] [Reference Citation Analysis]
|
| 48 |
Saigusa D, Matsukawa N, Hishinuma E, Koshiba S. Identification of biomarkers to diagnose diseases and find adverse drug reactions by metabolomics. Drug Metab Pharmacokinet 2021;37:100373. [PMID: 33631535 DOI: 10.1016/j.dmpk.2020.11.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 49 |
Federici M. Our second genome and the impact on metabolic disorders: why gut microbiome is an important player in diabetes and associated abnormalities. Acta Diabetol 2019;56:491-2. [DOI: 10.1007/s00592-019-01315-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 50 |
Liu X, Zheng H, Lu R, Huang H, Zhu H, Yin C, Mo Y, Wu J, Liu X, Deng M, Li D, Cheng B, Wu F, Liang Y, Guo H, Song H, Su Z. Intervening Effects of Total Alkaloids of Corydalis saxicola Bunting on Rats With Antibiotic-Induced Gut Microbiota Dysbiosis Based on 16S rRNA Gene Sequencing and Untargeted Metabolomics Analyses. Front Microbiol 2019;10:1151. [PMID: 31214133 DOI: 10.3389/fmicb.2019.01151] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 51 |
He LH, Yao DH, Wang LY, Zhang L, Bai XL. Gut Microbiome-Mediated Alteration of Immunity, Inflammation, and Metabolism Involved in the Regulation of Non-alcoholic Fatty Liver Disease. Front Microbiol 2021;12:761836. [PMID: 34795655 DOI: 10.3389/fmicb.2021.761836] [Reference Citation Analysis]
|
| 52 |
Hrncir T, Hrncirova L, Kverka M, Hromadka R, Machova V, Trckova E, Kostovcikova K, Kralickova P, Krejsek J, Tlaskalova-Hogenova H. Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions. Microorganisms 2021;9:957. [PMID: 33946843 DOI: 10.3390/microorganisms9050957] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 53 |
Lefebvre P, Staels B. Hepatic sexual dimorphism - implications for non-alcoholic fatty liver disease. Nat Rev Endocrinol 2021;17:662-70. [PMID: 34417588 DOI: 10.1038/s41574-021-00538-6] [Reference Citation Analysis]
|
| 54 |
Bifari F, Manfrini R, Dei Cas M, Berra C, Siano M, Zuin M, Paroni R, Folli F. Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Pharmacol Res 2018;137:219-29. [PMID: 30359962 DOI: 10.1016/j.phrs.2018.09.025] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 55 |
Higarza SG, Arboleya S, Arias JL, Gueimonde M, Arias N. Akkermansia muciniphila and environmental enrichment reverse cognitive impairment associated with high-fat high-cholesterol consumption in rats. Gut Microbes 2021;13:1-20. [PMID: 33678110 DOI: 10.1080/19490976.2021.1880240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 56 |
Pietzner M, Stewart ID, Raffler J, Khaw KT, Michelotti GA, Kastenmüller G, Wareham NJ, Langenberg C. Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med 2021;27:471-9. [PMID: 33707775 DOI: 10.1038/s41591-021-01266-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 57 |
Tilg H, Adolph TE, Moschen AR. Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade. Hepatology. 2021;73:833-842. [PMID: 32780879 DOI: 10.1002/hep.31518] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 35.0] [Reference Citation Analysis]
|
| 58 |
Menghini R, Federici M. MicroRNA 221/222 cluster kicks out Timp-3 to inflame the liver. EBioMedicine 2018;37:7-8. [PMID: 30344123 DOI: 10.1016/j.ebiom.2018.10.040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 59 |
Leyrolle Q, Cserjesi R, Mulders MDGH, Zamariola G, Hiel S, Gianfrancesco MA, Rodriguez J, Portheault D, Amadieu C, Leclercq S, Bindels LB, Neyrinck AM, Cani PD, Karkkainen O, Hanhineva K, Lanthier N, Trefois P, Paquot N, Cnop M, Thissen JP, Klein O, Luminet O, Delzenne NM. Specific gut microbial, biological, and psychiatric profiling related to binge eating disorders: A cross-sectional study in obese patients. Clin Nutr 2021;40:2035-44. [PMID: 33023763 DOI: 10.1016/j.clnu.2020.09.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 60 |
Iruarrizaga-lejarreta M, Arretxe E, Alonso C. Using metabolomics to develop precision medicine strategies to treat nonalcoholic steatohepatitis. Expert Review of Precision Medicine and Drug Development 2019;4:283-97. [DOI: 10.1080/23808993.2019.1685379] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 61 |
Giuffrè M, Campigotto M, Campisciano G, Comar M, Crocè LS. A story of liver and gut microbes: how does the intestinal flora affect liver disease? A review of the literature. Am J Physiol Gastrointest Liver Physiol 2020;318:G889-906. [PMID: 32146836 DOI: 10.1152/ajpgi.00161.2019] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 13.5] [Reference Citation Analysis]
|
| 62 |
Zhu Y, Shui X, Liang Z, Huang Z, Qi Y, He Y, Chen C, Luo H, Lei W. Gut microbiota metabolites as integral mediators in cardiovascular diseases (Review). Int J Mol Med 2020;46:936-48. [PMID: 32705240 DOI: 10.3892/ijmm.2020.4674] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 63 |
Fei N, Bruneau A, Zhang X, Wang R, Wang J, Rabot S, Gérard P, Zhao L. Endotoxin Producers Overgrowing in Human Gut Microbiota as the Causative Agents for Nonalcoholic Fatty Liver Disease. mBio 2020;11:e03263-19. [PMID: 32019793 DOI: 10.1128/mBio.03263-19] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 64 |
Wu WK, Chen YH, Lee PC, Yang PJ, Chang CC, Liu KL, Hsu CC, Huang CC, Chuang HL, Sheen LY, Liu CJ, Wu MS. Mining Gut Microbiota From Bariatric Surgery for MAFLD. Front Endocrinol (Lausanne) 2021;12:612946. [PMID: 33897617 DOI: 10.3389/fendo.2021.612946] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 65 |
Loo RL, Chan Q, Nicholson JK, Holmes E. Balancing the Equation: A Natural History of Trimethylamine and Trimethylamine-N-oxide. J Proteome Res 2022. [PMID: 35142516 DOI: 10.1021/acs.jproteome.1c00851] [Reference Citation Analysis]
|
| 66 |
Williams SG, Wolin SL. The Autoantigen Repertoire and the Microbial RNP World. Trends Mol Med 2021;27:422-35. [PMID: 33722441 DOI: 10.1016/j.molmed.2021.02.003] [Reference Citation Analysis]
|
| 67 |
Chen J, Vitetta L. Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications. Int J Mol Sci 2020;21:E5214. [PMID: 32717871 DOI: 10.3390/ijms21155214] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 68 |
Tincopa MA. Diagnostic and interventional circulating biomarkers in nonalcoholic steatohepatitis. Endocrinol Diabetes Metab 2020;3:e00177. [PMID: 33102798 DOI: 10.1002/edm2.177] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 69 |
Villette R, Kc P, Beliard S, Salas Tapia MF, Rainteau D, Guerin M, Lesnik P. Unraveling Host-Gut Microbiota Dialogue and Its Impact on Cholesterol Levels. Front Pharmacol 2020;11:278. [PMID: 32308619 DOI: 10.3389/fphar.2020.00278] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 70 |
Zhou J, Tripathi M, Sinha RA, Singh BK, Yen PM. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. Hepatoma Res 2021;7:11. [PMID: 33490737 DOI: 10.20517/2394-5079.2020.134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 71 |
Bence KK, Birnbaum MJ. Metabolic drivers of non-alcoholic fatty liver disease. Mol Metab 2021;50:101143. [PMID: 33346069 DOI: 10.1016/j.molmet.2020.101143] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 72 |
Sharpton SR, Podlaha O, Chuang J, Gindin Y, Myers RP, Loomba R. Changes in the gut microbiome associated with liver stiffness improvement in nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2022;15:175628482210982. [DOI: 10.1177/17562848221098243] [Reference Citation Analysis]
|
| 73 |
Kappel BA, Lehrke M. Mikrobiom, Diabetes und Herz: neue Zusammenhänge? Herz 2019;44:223-30. [DOI: 10.1007/s00059-019-4791-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 74 |
Guo J, Zhang S, Fang L, Huang J, Wang Q, Wang C, Chen M. In utero exposure to phenanthrene induces hepatic steatosis in F1 adult female mice. Chemosphere 2020;258:127360. [PMID: 32554016 DOI: 10.1016/j.chemosphere.2020.127360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 75 |
Sui G, Jia L, Quan D, Zhao N, Yang G. Activation of the gut microbiota-kynurenine-liver axis contributes to the development of nonalcoholic hepatic steatosis in nondiabetic adults. Aging (Albany NY) 2021;13:21309-24. [PMID: 34473644 DOI: 10.18632/aging.203460] [Reference Citation Analysis]
|
| 76 |
Cioffi CE, Narayan KMV, Liu K, Uppal K, Jones DP, Tran V, Yu T, Alvarez JA, Bellissimo MP, Maner-Smith KM, Pierpoint B, Caprio S, Santoro N, Vos MB. Hepatic fat is a stronger correlate of key clinical and molecular abnormalities than visceral and abdominal subcutaneous fat in youth. BMJ Open Diabetes Res Care 2020;8:e001126. [PMID: 32699106 DOI: 10.1136/bmjdrc-2019-001126] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 77 |
Long NP, Nghi TD, Kang YP, Anh NH, Kim HM, Park SK, Kwon SW. Toward a Standardized Strategy of Clinical Metabolomics for the Advancement of Precision Medicine. Metabolites 2020;10:E51. [PMID: 32013105 DOI: 10.3390/metabo10020051] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 78 |
Jadhav K, Cohen TS. Can You Trust Your Gut? Front Endocrinol (Lausanne). 2020;11:592157. [PMID: 33193105 DOI: 10.3389/fendo.2020.592157] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 79 |
Mayneris-Perxachs J, Cardellini M, Hoyles L, Latorre J, Davato F, Moreno-Navarrete JM, Arnoriaga-Rodríguez M, Serino M, Abbott J, Barton RH, Puig J, Fernández-Real X, Ricart W, Tomlinson C, Woodbridge M, Gentileschi P, Butcher SA, Holmes E, Nicholson JK, Pérez-Brocal V, Moya A, Clain DM, Burcelin R, Dumas ME, Federici M, Fernández-Real JM. Iron status influences non-alcoholic fatty liver disease in obesity through the gut microbiome. Microbiome 2021;9:104. [PMID: 33962692 DOI: 10.1186/s40168-021-01052-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 80 |
Canfora EE, Meex RCR, Venema K, Blaak EE. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol. 2019;15:261-273. [PMID: 30670819 DOI: 10.1038/s41574-019-0156-z] [Cited by in Crossref: 288] [Cited by in F6Publishing: 271] [Article Influence: 96.0] [Reference Citation Analysis]
|
| 81 |
Hyun CK. Molecular and Pathophysiological Links between Metabolic Disorders and Inflammatory Bowel Diseases. Int J Mol Sci 2021;22:9139. [PMID: 34502047 DOI: 10.3390/ijms22179139] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 82 |
Ganesan R, Jeong J, Kim DJ, Suk KT. Recent Trends of Microbiota-Based Microbial Metabolites Metabolism in Liver Disease. Front Med 2022;9:841281. [DOI: 10.3389/fmed.2022.841281] [Reference Citation Analysis]
|
| 83 |
[DOI: 10.1101/866459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 84 |
D'Amato A, Di Cesare Mannelli L, Lucarini E, Man AL, Le Gall G, Branca JJV, Ghelardini C, Amedei A, Bertelli E, Regoli M, Pacini A, Luciani G, Gallina P, Altera A, Narbad A, Gulisano M, Hoyles L, Vauzour D, Nicoletti C. Faecal microbiota transplant from aged donor mice affects spatial learning and memory via modulating hippocampal synaptic plasticity- and neurotransmission-related proteins in young recipients. Microbiome 2020;8:140. [PMID: 33004079 DOI: 10.1186/s40168-020-00914-w] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 85 |
Rubio C, Puerto M, García-Rodríquez JJ, Lu VB, García-Martínez I, Alén R, Sanmartín-Salinas P, Toledo-Lobo MV, Saiz J, Ruperez J, Barbas C, Menchén L, Gribble FM, Reimann F, Guijarro LG, Carrascosa JM, Valverde ÁM. Impact of global PTP1B deficiency on the gut barrier permeability during NASH in mice. Mol Metab 2020;35:100954. [PMID: 32244182 DOI: 10.1016/j.molmet.2020.01.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 86 |
Hoyles L, Pontifex MG, Rodriguez-Ramiro I, Anis-Alavi MA, Jelane KS, Snelling T, Solito E, Fonseca S, Carvalho AL, Carding SR, Müller M, Glen RC, Vauzour D, McArthur S. Regulation of blood-brain barrier integrity by microbiome-associated methylamines and cognition by trimethylamine N-oxide. Microbiome 2021;9:235. [PMID: 34836554 DOI: 10.1186/s40168-021-01181-z] [Reference Citation Analysis]
|
| 87 |
Yang M, Khoukaz L, Qi X, Kimchi ET, Staveley-O'Carroll KF, Li G. Diet and Gut Microbiota Interaction-Derived Metabolites and Intrahepatic Immune Response in NAFLD Development and Treatment. Biomedicines 2021;9:1893. [PMID: 34944709 DOI: 10.3390/biomedicines9121893] [Reference Citation Analysis]
|
| 88 |
Zeng T, Yu X, Chen Z. Applying artificial intelligence in the microbiome for gastrointestinal diseases: A review. J Gastroenterol Hepatol 2021;36:832-40. [PMID: 33880762 DOI: 10.1111/jgh.15503] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 89 |
Dong TS, Jacobs JP. Nonalcoholic fatty liver disease and the gut microbiome: Are bacteria responsible for fatty liver? Exp Biol Med (Maywood) 2019;244:408-18. [PMID: 30871368 DOI: 10.1177/1535370219836739] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 90 |
Zhou D, Fan JG. Microbial metabolites in non-alcoholic fatty liver disease. World J Gastroenterol 2019; 25(17): 2019-2028 [PMID: 31114130 DOI: 10.3748/wjg.v25.i17.2019] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 91 |
Aron-wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom AG, Verheij J, Nieuwdorp M, Clément K. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 2020;17:279-97. [DOI: 10.1038/s41575-020-0269-9] [Cited by in Crossref: 103] [Cited by in F6Publishing: 103] [Article Influence: 51.5] [Reference Citation Analysis]
|
| 92 |
Song Q, Zhang X. The Role of Gut–Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC. Biomedicines 2022;10:524. [DOI: 10.3390/biomedicines10030524] [Reference Citation Analysis]
|
| 93 |
Emamat H, Ghalandari H, Tangestani H, Abdollahi A, Hekmatdoost A. Artificial sweeteners are related to non-alcoholic fatty liver disease: Microbiota dysbiosis as a novel potential mechanism. EXCLI J 2020;19:620-6. [PMID: 32483408 DOI: 10.17179/excli2020-1226] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
|
| 94 |
Eslam M, Sanyal AJ, George J, Sanyal A, Neuschwander-tetri B, Tiribelli C, Kleiner DE, Brunt E, Bugianesi E, Yki-järvinen H, Grønbæk H, Cortez-pinto H, George J, Fan J, Valenti L, Abdelmalek M, Romero-gomez M, Rinella M, Arrese M, Eslam M, Bedossa P, Newsome PN, Anstee QM, Jalan R, Bataller R, Loomba R, Sookoian S, Sarin SK, Harrison S, Kawaguchi T, Wong VW, Ratziu V, Yilmaz Y, Younossi Z. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology 2020;158:1999-2014.e1. [DOI: 10.1053/j.gastro.2019.11.312] [Cited by in Crossref: 428] [Cited by in F6Publishing: 423] [Article Influence: 214.0] [Reference Citation Analysis]
|
| 95 |
Burz SD, Monnoye M, Philippe C, Farin W, Ratziu V, Strozzi F, Paillarse JM, Chêne L, Blottière HM, Gérard P. Fecal Microbiota Transplant from Human to Mice Gives Insights into the Role of the Gut Microbiota in Non-Alcoholic Fatty Liver Disease (NAFLD). Microorganisms 2021;9:199. [PMID: 33477939 DOI: 10.3390/microorganisms9010199] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 96 |
Niederseer D, Wernly B, Aigner E, Stickel F, Datz C. NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. J Clin Med 2021;10:467. [PMID: 33530440 DOI: 10.3390/jcm10030467] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 97 |
Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature 2019;576:51-60. [PMID: 31802013 DOI: 10.1038/s41586-019-1797-8] [Cited by in Crossref: 172] [Cited by in F6Publishing: 157] [Article Influence: 57.3] [Reference Citation Analysis]
|
| 98 |
Baffy G. Potential mechanisms linking gut microbiota and portal hypertension. Liver Int. 2019;39:598-609. [PMID: 30312513 DOI: 10.1111/liv.13986] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 99 |
Nilsson Å, Duan RD. Pancreatic and mucosal enzymes in choline phospholipid digestion. Am J Physiol Gastrointest Liver Physiol 2019;316:G425-45. [PMID: 30576217 DOI: 10.1152/ajpgi.00320.2018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 100 |
Wirbel J, Zych K, Essex M, Karcher N, Kartal E, Salazar G, Bork P, Sunagawa S, Zeller G. Microbiome meta-analysis and cross-disease comparison enabled by the SIAMCAT machine learning toolbox. Genome Biol 2021;22:93. [PMID: 33785070 DOI: 10.1186/s13059-021-02306-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 101 |
Chu H, Duan Y, Yang L, Schnabl B. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. Gut. 2019;68:359-370. [PMID: 30171065 DOI: 10.1136/gutjnl-2018-316307] [Cited by in Crossref: 115] [Cited by in F6Publishing: 116] [Article Influence: 28.8] [Reference Citation Analysis]
|
| 102 |
Di Ciaula A, Baj J, Garruti G, Celano G, De Angelis M, Wang HH, Di Palo DM, Bonfrate L, Wang DQ, Portincasa P. Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. J Clin Med 2020;9:E2648. [PMID: 32823983 DOI: 10.3390/jcm9082648] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 103 |
Knudsen C, Neyrinck AM, Leyrolle Q, Baldin P, Leclercq S, Rodriguez J, Beaumont M, Cani PD, Bindels LB, Lanthier N, Delzenne NM. Hepatoprotective Effects of Indole, a Gut Microbial Metabolite, in Leptin-Deficient Obese Mice. J Nutr 2021;151:1507-16. [PMID: 33693866 DOI: 10.1093/jn/nxab032] [Reference Citation Analysis]
|
| 104 |
Sharpton SR, Schnabl B, Knight R, Loomba R. Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease. Cell Metab 2021;33:21-32. [PMID: 33296678 DOI: 10.1016/j.cmet.2020.11.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 105 |
Alferink LJM, Radjabzadeh D, Erler NS, Vojinovic D, Medina-Gomez C, Uitterlinden AG, de Knegt RJ, Amin N, Ikram MA, Janssen HLA, Kiefte-de Jong JC, Metselaar HJ, van Duijn CM, Kraaij R, Darwish Murad S. Microbiomics, Metabolomics, Predicted Metagenomics, and Hepatic Steatosis in a Population-Based Study of 1,355 Adults.Hepatology. 2021;73:968-982. [PMID: 32530501 DOI: 10.1002/hep.31417] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 106 |
Jian H, Xu Q, Wang X, Liu Y, Miao S, Li Y, Mou T, Dong X, Zou X. Amino Acid and Fatty Acid Metabolism Disorders Trigger Oxidative Stress and Inflammatory Response in Excessive Dietary Valine-Induced NAFLD of Laying Hens. Front Nutr 2022;9:849767. [DOI: 10.3389/fnut.2022.849767] [Reference Citation Analysis]
|
| 107 |
Hrncir T. Gut Microbiota Dysbiosis: Triggers, Consequences, Diagnostic and Therapeutic Options. Microorganisms 2022;10:578. [DOI: 10.3390/microorganisms10030578] [Reference Citation Analysis]
|
| 108 |
Hoozemans J, de Brauw M, Nieuwdorp M, Gerdes V. Gut Microbiome and Metabolites in Patients with NAFLD and after Bariatric Surgery: A Comprehensive Review. Metabolites 2021;11:353. [PMID: 34072995 DOI: 10.3390/metabo11060353] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 109 |
Tilg H, Zmora N, Adolph TE, Elinav E. The intestinal microbiota fuelling metabolic inflammation. Nat Rev Immunol 2020;20:40-54. [DOI: 10.1038/s41577-019-0198-4] [Cited by in Crossref: 179] [Cited by in F6Publishing: 171] [Article Influence: 59.7] [Reference Citation Analysis]
|
| 110 |
Horne RG, Yu Y, Zhang R, Abdalqadir N, Rossi L, Surette M, Sherman PM, Adeli K. High Fat-High Fructose Diet-Induced Changes in the Gut Microbiota Associated with Dyslipidemia in Syrian Hamsters. Nutrients 2020;12:E3557. [PMID: 33233570 DOI: 10.3390/nu12113557] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 111 |
Domenech-Ximenos B, Cuba V, Daunis-I-Estadella P, Thió-Henestrosa S, Jaldo F, Biarnes C, Molina X, Xifra G, Ricart W, Bardera A, Boada I, Essig M, Pedraza S, Federici M, Fernández-Real JM, Puig J. Bariatric Surgery-Induced Changes in Intima-Media Thickness and Cardiovascular Risk Factors in Class 3 Obesity: A 3-Year Follow-Up Study. Obesity (Silver Spring) 2020;28:1663-70. [PMID: 32776483 DOI: 10.1002/oby.22905] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 112 |
Baciu C, Shin J, Hsin M, Cypel M, Keshavjee S, Liu M. Altered purine metabolism at reperfusion affects clinical outcome in lung transplantation. Thorax 2022:thoraxjnl-2021-217498. [PMID: 35450941 DOI: 10.1136/thoraxjnl-2021-217498] [Reference Citation Analysis]
|
| 113 |
Alves A, Bassot A, Bulteau AL, Pirola L, Morio B. Glycine Metabolism and Its Alterations in Obesity and Metabolic Diseases. Nutrients 2019;11:E1356. [PMID: 31208147 DOI: 10.3390/nu11061356] [Cited by in Crossref: 62] [Cited by in F6Publishing: 48] [Article Influence: 20.7] [Reference Citation Analysis]
|
| 114 |
Peiseler M, Tacke F. Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma. Cancers (Basel) 2021;13:730. [PMID: 33578800 DOI: 10.3390/cancers13040730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 115 |
Grabherr F, Grander C, Effenberger M, Adolph TE, Tilg H. Gut Dysfunction and Non-alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne). 2019;10:611. [PMID: 31555219 DOI: 10.3389/fendo.2019.00611] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 116 |
Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M, Clément K. Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity? Gastroenterology 2020;158:1881-98. [PMID: 32044317 DOI: 10.1053/j.gastro.2020.01.049] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 12.5] [Reference Citation Analysis]
|
| 117 |
Sookoian S, Salatino A, Castaño GO, Landa MS, Fijalkowky C, Garaycoechea M, Pirola CJ. Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease. Gut 2020;69:1483-91. [DOI: 10.1136/gutjnl-2019-318811] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 17.5] [Reference Citation Analysis]
|
| 118 |
Albhaisi SAM, Bajaj JS, Sanyal AJ. Role of gut microbiota in liver disease. Am J Physiol Gastrointest Liver Physiol 2020;318:G84-98. [PMID: 31657225 DOI: 10.1152/ajpgi.00118.2019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 119 |
Li R, Mao Z, Ye X, Zuo T. Human Gut Microbiome and Liver Diseases: From Correlation to Causation. Microorganisms 2021;9:1017. [PMID: 34066850 DOI: 10.3390/microorganisms9051017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 120 |
Chakrabarti A, Geurts L, Hoyles L, Iozzo P, Kraneveld AD, La Fata G, Miani M, Patterson E, Pot B, Shortt C, Vauzour D. The microbiota–gut–brain axis: pathways to better brain health. Perspectives on what we know, what we need to investigate and how to put knowledge into practice. Cell Mol Life Sci 2022;79. [DOI: 10.1007/s00018-021-04060-w] [Reference Citation Analysis]
|
| 121 |
Liu Y, Luo Y, Wang X, Luo L, Sun K, Zeng L. Gut Microbiome and Metabolome Response of Pu-erh Tea on Metabolism Disorder Induced by Chronic Alcohol Consumption. J Agric Food Chem 2020;68:6615-27. [PMID: 32419453 DOI: 10.1021/acs.jafc.0c01947] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 122 |
Castillo-Castro C, Martagón-Rosado AJ, Ortiz-Lopez R, Garrido-Treviño LF, Villegas-Albo M, Bosques-Padilla FJ. Promising diagnostic biomarkers of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: From clinical proteomics to microbiome. World J Hepatol 2021; 13(11): 1494-1511 [PMID: 34904026 DOI: 10.4254/wjh.v13.i11.1494] [Reference Citation Analysis]
|
| 123 |
Li R, Bu Y, Yang C, Wang J. Effects of Lipid Deposition on Viscoelastic Response in Human Hepatic Cell Line HepG2. Front Physiol 2021;12:684121. [PMID: 34539426 DOI: 10.3389/fphys.2021.684121] [Reference Citation Analysis]
|
| 124 |
Kolodziejczyk AA, Zheng D, Shibolet O, Elinav E. The role of the microbiome in NAFLD and NASH. EMBO Mol Med. 2019;11: e9302. [PMID: 30591521 DOI: 10.15252/emmm.201809302] [Cited by in Crossref: 131] [Cited by in F6Publishing: 121] [Article Influence: 43.7] [Reference Citation Analysis]
|
| 125 |
Rackaityte E, Lynch SV. Rules of engagement in the gut microbiome. Nat Med 2018;24:1642-4. [DOI: 10.1038/s41591-018-0242-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 126 |
Zhang S, Zhao J, Xie F, He H, Johnston LJ, Dai X, Wu C, Ma X. Dietary fiber-derived short-chain fatty acids: A potential therapeutic target to alleviate obesity-related nonalcoholic fatty liver disease. Obes Rev 2021;:e13316. [PMID: 34279051 DOI: 10.1111/obr.13316] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 127 |
Edwards PT, Kashyap PC, Preidis GA. Microbiota on biotics: probiotics, prebiotics, and synbiotics to optimize growth and metabolism. Am J Physiol Gastrointest Liver Physiol 2020;319:G382-90. [PMID: 32755308 DOI: 10.1152/ajpgi.00028.2020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 128 |
Gheorghe CE, Ritz NL, Martin JA, Wardill HR, Cryan JF, Clarke G. Investigating causality with fecal microbiota transplantation in rodents: applications, recommendations and pitfalls. Gut Microbes 2021;13:1941711. [PMID: 34328058 DOI: 10.1080/19490976.2021.1941711] [Reference Citation Analysis]
|
| 129 |
Ni Y, Ni L, Zhuge F, Fu Z. The Gut Microbiota and Its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease. Mol Nutr Food Res 2020;64:e2000375. [PMID: 32738185 DOI: 10.1002/mnfr.202000375] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 130 |
Lang S, Schnabl B. Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future. Cell Host Microbe 2020;28:233-44. [PMID: 32791115 DOI: 10.1016/j.chom.2020.07.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 131 |
Zhao M, Chen S, Ji X, Shen X, You J, Liang X, Yin H, Zhao L. Current innovations in nutraceuticals and functional foods for intervention of non-alcoholic fatty liver disease. Pharmacol Res 2021;166:105517. [PMID: 33636349 DOI: 10.1016/j.phrs.2021.105517] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 132 |
Luo Z, Xu W, Zhang Y, Di L, Shan J. A review of saponin intervention in metabolic syndrome suggests further study on intestinal microbiota. Pharmacol Res 2020;160:105088. [PMID: 32683035 DOI: 10.1016/j.phrs.2020.105088] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 133 |
Bernard M, Rué O, Mariadassou M, Pascal G. FROGS: a powerful tool to analyse the diversity of fungi with special management of internal transcribed spacers. Brief Bioinform 2021;22:bbab318. [PMID: 34410336 DOI: 10.1093/bib/bbab318] [Reference Citation Analysis]
|
| 134 |
Richard MA, Brown AL, Belmont JW, Scheurer ME, Arroyo VM, Foster KL, Kern KD, Hudson MM, Leisenring WM, Okcu MF, Sapkota Y, Yasui Y, Morton LM, Chanock SJ, Robison LL, Armstrong GT, Bhatia S, Oeffinger KC, Lupo PJ, Kamdar KY. Genetic variation in the body mass index of adult survivors of childhood acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort. Cancer 2021;127:310-8. [PMID: 33048379 DOI: 10.1002/cncr.33258] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 135 |
Flores YN, Amoon AT, Su B, Velazquez-Cruz R, Ramírez-Palacios P, Salmerón J, Rivera-Paredez B, Sinsheimer JS, Lusis AJ, Huertas-Vazquez A, Saab S, Glenn BA, May FP, Williams KJ, Bastani R, Bensinger SJ. Serum lipids are associated with nonalcoholic fatty liver disease: a pilot case-control study in Mexico. Lipids Health Dis 2021;20:136. [PMID: 34629052 DOI: 10.1186/s12944-021-01526-5] [Reference Citation Analysis]
|
| 136 |
Chen Y, Zhou J, Wang L. Role and Mechanism of Gut Microbiota in Human Disease. Front Cell Infect Microbiol 2021;11:625913. [PMID: 33816335 DOI: 10.3389/fcimb.2021.625913] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 137 |
Federici M. Gut microbiome and microbial metabolites: a new system affecting metabolic disorders. J Endocrinol Invest 2019;42:1011-8. [PMID: 30788772 DOI: 10.1007/s40618-019-01022-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 138 |
Wu WK, Hsu CC, Sheen LY, Wu MS. Measurement of gut microbial metabolites in cardiometabolic health and translational research. Rapid Commun Mass Spectrom 2020;34 Suppl 1:e8537. [PMID: 31344762 DOI: 10.1002/rcm.8537] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 139 |
Oh TG, Kim SM, Caussy C, Fu T, Guo J, Bassirian S, Singh S, Madamba EV, Bettencourt R, Richards L, Yu RT, Atkins AR, Huan T, Brenner DA, Sirlin CB, Downes M, Evans RM, Loomba R. A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis. Cell Metab 2020;32:878-888.e6. [PMID: 32610095 DOI: 10.1016/j.cmet.2020.06.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 140 |
Wang R, Tang R, Li B, Ma X, Schnabl B, Tilg H. Gut microbiome, liver immunology, and liver diseases.Cell Mol Immunol. 2021;18:4-17. [PMID: 33318628 DOI: 10.1038/s41423-020-00592-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 141 |
Lynch SV, Ng SC, Shanahan F, Tilg H. Translating the gut microbiome: ready for the clinic? Nat Rev Gastroenterol Hepatol 2019;16:656-61. [PMID: 31562390 DOI: 10.1038/s41575-019-0204-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 142 |
Vancells Lujan P, Viñas Esmel E, Sacanella Meseguer E. Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development. Nutrients 2021;13:1442. [PMID: 33923255 DOI: 10.3390/nu13051442] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 143 |
Soderborg TK, Clark SE, Mulligan CE, Janssen RC, Babcock L, Ir D, Young B, Krebs N, Lemas DJ, Johnson LK, Weir T, Lenz LL, Frank DN, Hernandez TL, Kuhn KA, D'Alessandro A, Barbour LA, El Kasmi KC, Friedman JE. The gut microbiota in infants of obese mothers increases inflammation and susceptibility to NAFLD. Nat Commun. 2018;9:4462. [PMID: 30367045 DOI: 10.1038/s41467-018-06929-0] [Cited by in Crossref: 86] [Cited by in F6Publishing: 81] [Article Influence: 21.5] [Reference Citation Analysis]
|
| 144 |
Luo H, Wu H, Wang L, Xiao S, Lu Y, Liu C, Yu X, Zhang X, Wang Z, Tang L. Hepatoprotective effects of Cassiae Semen on mice with non-alcoholic fatty liver disease based on gut microbiota. Commun Biol 2021;4:1357. [PMID: 34862475 DOI: 10.1038/s42003-021-02883-8] [Reference Citation Analysis]
|
| 145 |
Ji X, Chen M, Zhao M, Song Y, Lin Y, Yin H, Zhao L. Effects of chitooligosaccharides on the rebalance of gut microorganisms and their metabolites in patients with nonalcoholic fatty liver disease. Journal of Functional Foods 2021;77:104333. [DOI: 10.1016/j.jff.2020.104333] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 146 |
Wang T, Guo XK, Xu H. Disentangling the Progression of Non-alcoholic Fatty Liver Disease in the Human Gut Microbiota. Front Microbiol 2021;12:728823. [PMID: 34721326 DOI: 10.3389/fmicb.2021.728823] [Reference Citation Analysis]
|
| 147 |
Rodriguez J, Olivares M, Delzenne NM. Implication of the Gut Microbiota in Metabolic Inflammation Associated with Nutritional Disorders and Obesity. Mol Nutr Food Res 2021;65:e1900481. [PMID: 33111450 DOI: 10.1002/mnfr.201900481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 148 |
Kappel BA, De Angelis L, Heiser M, Ballanti M, Stoehr R, Goettsch C, Mavilio M, Artati A, Paoluzi OA, Adamski J, Mingrone G, Staels B, Burcelin R, Monteleone G, Menghini R, Marx N, Federici M. Cross-omics analysis revealed gut microbiome-related metabolic pathways underlying atherosclerosis development after antibiotics treatment. Mol Metab 2020;36:100976. [PMID: 32251665 DOI: 10.1016/j.molmet.2020.100976] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 149 |
Iruzubieta P, Medina JM, Fernández-López R, Crespo J, de la Cruz F. A Role for Gut Microbiome Fermentative Pathways in Fatty Liver Disease Progression. J Clin Med 2020;9:E1369. [PMID: 32392712 DOI: 10.3390/jcm9051369] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 150 |
Jiang L, Schnabl B. Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know? Physiology (Bethesda) 2020;35:261-74. [PMID: 32490750 DOI: 10.1152/physiol.00005.2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 151 |
Huang L, Wang L, Hu X, Chen S, Tao Y, Su H, Yang J, Xu W, Vedarethinam V, Wu S, Liu B, Wan X, Lou J, Wang Q, Qian K. Machine learning of serum metabolic patterns encodes early-stage lung adenocarcinoma. Nat Commun 2020;11:3556. [PMID: 32678093 DOI: 10.1038/s41467-020-17347-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 152 |
Long MT, Gandhi S, Loomba R. Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease. Metabolism 2020;111S:154259. [PMID: 32387227 DOI: 10.1016/j.metabol.2020.154259] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 153 |
Vijay A, Valdes AM. Role of the gut microbiome in chronic diseases: a narrative review. Eur J Clin Nutr 2021. [PMID: 34584224 DOI: 10.1038/s41430-021-00991-6] [Reference Citation Analysis]
|
| 154 |
Xie C, Halegoua-DeMarzio D. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter? Nutrients. 2019;11. [PMID: 31752378 DOI: 10.3390/nu11112837] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 155 |
Golonka RM, Vijay-Kumar M. Atypical immunometabolism and metabolic reprogramming in liver cancer: Deciphering the role of gut microbiome. Adv Cancer Res 2021;149:171-255. [PMID: 33579424 DOI: 10.1016/bs.acr.2020.10.004] [Reference Citation Analysis]
|
| 156 |
Gil-Gómez A, Brescia P, Rescigno M, Romero-Gómez M. Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers. Semin Liver Dis 2021;41:191-205. [PMID: 34107545 DOI: 10.1055/s-0041-1723752] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 157 |
Loomba R, Ling L, Dinh DM, DePaoli AM, Lieu HD, Harrison SA, Sanyal AJ. The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in NASH. Hepatology 2021;73:126-43. [PMID: 32794259 DOI: 10.1002/hep.31523] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 158 |
Ghosh S, Yang X, Wang L, Zhang C, Zhao L. Active phase prebiotic feeding alters gut microbiota, induces weight-independent alleviation of hepatic steatosis and serum cholesterol in high-fat diet-fed mice. Comput Struct Biotechnol J 2021;19:448-58. [PMID: 33510856 DOI: 10.1016/j.csbj.2020.12.011] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 159 |
Hamada T, Nowak JA, Milner DA jr. Song M, Ogino S. Integration of microbiology, molecular pathology, and epidemiology: a new paradigm to explore the pathogenesis of microbiome-driven neoplasms. J Pathol. 2019;247:615-628. [PMID: 30632609 DOI: 10.1002/path.5236] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 160 |
Lanthier N, Rodriguez J, Nachit M, Hiel S, Trefois P, Neyrinck AM, Cani PD, Bindels LB, Thissen JP, Delzenne NM. Microbiota analysis and transient elastography reveal new extra-hepatic components of liver steatosis and fibrosis in obese patients. Sci Rep 2021;11:659. [PMID: 33436764 DOI: 10.1038/s41598-020-79718-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 161 |
Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2020;72:558-577. [PMID: 31622696 DOI: 10.1016/j.jhep.2019.10.003] [Cited by in Crossref: 141] [Cited by in F6Publishing: 151] [Article Influence: 47.0] [Reference Citation Analysis]
|
| 162 |
Misra BB, Misra A. The chemical exposome of type 2 diabetes mellitus: Opportunities and challenges in the omics era. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2020;14:23-38. [DOI: 10.1016/j.dsx.2019.12.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 163 |
Dai X, Hou H, Zhang W, Liu T, Li Y, Wang S, Wang B, Cao H. Microbial Metabolites: Critical Regulators in NAFLD.Front Microbiol. 2020;11:567654. [PMID: 33117316 DOI: 10.3389/fmicb.2020.567654] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 164 |
Ribeiro PR, Teixeira RDS, Souza AR, Pereira TCS, Boffo EF, Carosio MGA, Ferreira AG, Oliveira RV, Rodrigues LEA, Silva JJ, de Souza AJ, Ladeia AMT. Blood plasma metabolomics of children and adolescents with sickle cell anaemia treated with hydroxycarbamide: a new tool for uncovering biochemical alterations. Br J Haematol 2021;192:922-31. [PMID: 33476407 DOI: 10.1111/bjh.17315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 165 |
Iacobini C, Pugliese G, Blasetti Fantauzzi C, Federici M, Menini S. Metabolically healthy versus metabolically unhealthy obesity. Metabolism 2019;92:51-60. [DOI: 10.1016/j.metabol.2018.11.009] [Cited by in Crossref: 87] [Cited by in F6Publishing: 76] [Article Influence: 29.0] [Reference Citation Analysis]
|
| 166 |
Ji X, Chang K, Chen M, Zhu L, Osman A, Yin H, Zhao L. In vitro fermentation of chitooligosaccharides and their effects on human fecal microbial community structure and metabolites. LWT 2021;144:111224. [DOI: 10.1016/j.lwt.2021.111224] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 167 |
Pan Y, Zhang X. Diet and gut microbiome in fatty liver and its associated liver cancer. J Gastroenterol Hepatol 2021. [PMID: 34664301 DOI: 10.1111/jgh.15713] [Reference Citation Analysis]
|
| 168 |
Orabi D, Osborn LJ, Fung K, Massey W, Horak AJ 3rd, Aucejo F, Choucair I, DeLucia B, Wang Z, Claesen J, Brown JM. A surgical method for continuous intraportal infusion of gut microbial metabolites in mice. JCI Insight 2021;6:145607. [PMID: 33986195 DOI: 10.1172/jci.insight.145607] [Reference Citation Analysis]
|
| 169 |
Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 2021;184:2537-64. [PMID: 33989548 DOI: 10.1016/j.cell.2021.04.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 170 |
Kimhofer T, Lodge S, Whiley L, Gray N, Loo RL, Lawler NG, Nitschke P, Bong SH, Morrison DL, Begum S, Richards T, Yeap BB, Smith C, Smith KGC, Holmes E, Nicholson JK. Integrative Modeling of Quantitative Plasma Lipoprotein, Metabolic, and Amino Acid Data Reveals a Multiorgan Pathological Signature of SARS-CoV-2 Infection. J Proteome Res 2020;19:4442-54. [PMID: 32806897 DOI: 10.1021/acs.jproteome.0c00519] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 18.5] [Reference Citation Analysis]
|
| 171 |
Mouzaki M, Loomba R. An update on the role of the microbiome in non-alcoholic fatty liver disease pathogenesis, diagnosis, and treatment. Curr Treat Options Gastroenterol 2020;18:270-80. [PMID: 33716495 DOI: 10.1007/s11938-020-00290-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 172 |
Manka P, Sydor S, Wase N, Best J, Brandenburg M, Hellbeck A, Schänzer J, Vilchez-Vargas R, Link A, Figge A, Jähnert A, von Arnim U, Coombes JD, Cubero FJ, Kahraman A, Kim MS, Kälsch J, Kinner S, Faber KN, Moshage H, Gerken G, Syn WK, Friedman SL, Canbay A, Bechmann LP. Anti-TNFα treatment in Crohn's disease: Impact on hepatic steatosis, gut-derived hormones and metabolic status. Liver Int 2021. [PMID: 34219348 DOI: 10.1111/liv.15003] [Reference Citation Analysis]
|
| 173 |
Grzych G, Vonghia L, Bout MA, Weyler J, Verrijken A, Dirinck E, Chevalier Curt MJ, Van Gaal L, Paumelle R, Francque S, Tailleux A, Haas JT, Staels B. Plasma BCAA Changes in Patients With NAFLD Are Sex Dependent. J Clin Endocrinol Metab 2020;105:dgaa175. [PMID: 32271385 DOI: 10.1210/clinem/dgaa175] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 174 |
Fernández-Real JM, Federici M, Burcelin R. Consider the microbiome in the equation! They were here before us...and hosted us! Rev Endocr Metab Disord 2019;20:383-5. [PMID: 31865508 DOI: 10.1007/s11154-019-09538-4] [Reference Citation Analysis]
|
| 175 |
Almeida JI, Tenreiro MF, Martinez-Santamaria L, Aspizua SG, Gisbert JP, Alves PM, Serra M, Baptista PM. Hallmarks of the human intestinal microbiome on liver maturation and function. J Hepatol 2021:S0168-8278(21)02152-8. [PMID: 34715263 DOI: 10.1016/j.jhep.2021.10.015] [Reference Citation Analysis]
|
| 176 |
Liu J, Lahousse L, Nivard MG, Bot M, Chen L, van Klinken JB, Thesing CS, Beekman M, van den Akker EB, Slieker RC, Waterham E, van der Kallen CJH, de Boer I, Li-Gao R, Vojinovic D, Amin N, Radjabzadeh D, Kraaij R, Alferink LJM, Murad SD, Uitterlinden AG, Willemsen G, Pool R, Milaneschi Y, van Heemst D, Suchiman HED, Rutters F, Elders PJM, Beulens JWJ, van der Heijden AAWA, van Greevenbroek MMJ, Arts ICW, Onderwater GLJ, van den Maagdenberg AMJM, Mook-Kanamori DO, Hankemeier T, Terwindt GM, Stehouwer CDA, Geleijnse JM, 't Hart LM, Slagboom PE, van Dijk KW, Zhernakova A, Fu J, Penninx BWJH, Boomsma DI, Demirkan A, Stricker BHC, van Duijn CM. Integration of epidemiologic, pharmacologic, genetic and gut microbiome data in a drug-metabolite atlas. Nat Med 2020;26:110-7. [PMID: 31932804 DOI: 10.1038/s41591-019-0722-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 177 |
Blaak EE, Canfora EE. Increased circulating choline, L-carnitine and TMAO levels are related to changes in adiposity during weight loss: role of the gut microbiota? Ann Transl Med 2018;6:S92. [PMID: 30740413 DOI: 10.21037/atm.2018.11.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 178 |
Laursen MF, Sakanaka M, von Burg N, Mörbe U, Andersen D, Moll JM, Pekmez CT, Rivollier A, Michaelsen KF, Mølgaard C, Lind MV, Dragsted LO, Katayama T, Frandsen HL, Vinggaard AM, Bahl MI, Brix S, Agace W, Licht TR, Roager HM. Bifidobacterium species associated with breastfeeding produce aromatic lactic acids in the infant gut. Nat Microbiol 2021;6:1367-82. [PMID: 34675385 DOI: 10.1038/s41564-021-00970-4] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 179 |
Lei M, Menon R, Manteiga S, Alden N, Hunt C, Alaniz RC, Lee K, Jayaraman A. Environmental Chemical Diethylhexyl Phthalate Alters Intestinal Microbiota Community Structure and Metabolite Profile in Mice. mSystems 2019;4:e00724-19. [PMID: 31822602 DOI: 10.1128/mSystems.00724-19] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 180 |
Moreno-Gonzalez M, Beraza N. The Role of the Microbiome in Liver Cancer. Cancers (Basel) 2021;13:2330. [PMID: 34066064 DOI: 10.3390/cancers13102330] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
|
| 181 |
Delzenne NM, Rodriguez J, Olivares M, Neyrinck AM. Microbiome response to diet: focus on obesity and related diseases. Rev Endocr Metab Disord 2020;21:369-80. [DOI: 10.1007/s11154-020-09572-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 182 |
Svegliati-Baroni G, Patrício B, Lioci G, Macedo MP, Gastaldelli A. Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH. Int J Mol Sci 2020;21:E5820. [PMID: 32823659 DOI: 10.3390/ijms21165820] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 183 |
Liu Y, Hou Y, Wang G, Zheng X, Hao H. Gut Microbial Metabolites of Aromatic Amino Acids as Signals in Host-Microbe Interplay. Trends Endocrinol Metab. 2020;31:818-834. [PMID: 32284282 DOI: 10.1016/j.tem.2020.02.012] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 15.5] [Reference Citation Analysis]
|
| 184 |
Loo RL, Lodge S, Kimhofer T, Bong SH, Begum S, Whiley L, Gray N, Lindon JC, Nitschke P, Lawler NG, Schäfer H, Spraul M, Richards T, Nicholson JK, Holmes E. Quantitative In-Vitro Diagnostic NMR Spectroscopy for Lipoprotein and Metabolite Measurements in Plasma and Serum: Recommendations for Analytical Artifact Minimization with Special Reference to COVID-19/SARS-CoV-2 Samples. J Proteome Res 2020;19:4428-41. [PMID: 32852212 DOI: 10.1021/acs.jproteome.0c00537] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 185 |
Sharpton SR, Yong GJM, Terrault NA, Lynch SV. Gut Microbial Metabolism and Nonalcoholic Fatty Liver Disease. Hepatol Commun 2019;3:29-43. [PMID: 30619992 DOI: 10.1002/hep4.1284] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 186 |
Liu Y, Wang Y, Ni Y, Cheung CK, Lam KS, Wang Y, Xia Z, Ye D, Guo J, Tse MA, Panagiotou G, Xu A. Gut Microbiome Fermentation Determines the Efficacy of Exercise for Diabetes Prevention. Cell Metabolism 2020;31:77-91.e5. [DOI: 10.1016/j.cmet.2019.11.001] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 31.5] [Reference Citation Analysis]
|
| 187 |
Li N, Li J, Zhang Q, Gao S, Quan X, Liu P, Xu C. Effects of endocrine disrupting chemicals in host health: Three-way interactions between environmental exposure, host phenotypic responses, and gut microbiota. Environ Pollut 2021;271:116387. [PMID: 33401209 DOI: 10.1016/j.envpol.2020.116387] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 188 |
Vallianou N, Christodoulatos GS, Karampela I, Tsilingiris D, Magkos F, Stratigou T, Kounatidis D, Dalamaga M. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. Biomolecules 2022;12:56. [DOI: 10.3390/biom12010056] [Reference Citation Analysis]
|
| 189 |
Yousefirizi F, Pierre Decazes, Amyar A, Ruan S, Saboury B, Rahmim A. AI-Based Detection, Classification and Prediction/Prognosis in Medical Imaging:: Towards Radiophenomics. PET Clin 2022;17:183-212. [PMID: 34809866 DOI: 10.1016/j.cpet.2021.09.010] [Reference Citation Analysis]
|
| 190 |
Yu SY, Xu L. The interplay between host cellular and gut microbial metabolism in NAFLD development and prevention. J Appl Microbiol 2021;131:564-82. [PMID: 33411984 DOI: 10.1111/jam.14992] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 191 |
Kolodziejczyk AA, Zheng D, Elinav E. Diet–microbiota interactions and personalized nutrition. Nat Rev Microbiol 2019;17:742-53. [DOI: 10.1038/s41579-019-0256-8] [Cited by in Crossref: 186] [Cited by in F6Publishing: 161] [Article Influence: 62.0] [Reference Citation Analysis]
|
| 192 |
Raja G, Gupta H, Gebru YA, Youn GS, Choi YR, Kim HS, Yoon SJ, Kim DJ, Kim TJ, Suk KT. Recent Advances of Microbiome-Associated Metabolomics Profiling in Liver Disease: Principles, Mechanisms, and Applications. Int J Mol Sci 2021;22:1160. [PMID: 33503844 DOI: 10.3390/ijms22031160] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 193 |
Tranah TH, Edwards LA, Schnabl B, Shawcross DL. Targeting the gut-liver-immune axis to treat cirrhosis. Gut 2021;70:982-94. [PMID: 33060124 DOI: 10.1136/gutjnl-2020-320786] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 194 |
Chen C, Fang S, Wei H, He M, Fu H, Xiong X, Zhou Y, Wu J, Gao J, Yang H, Huang L. Prevotella copri increases fat accumulation in pigs fed with formula diets. Microbiome 2021;9:175. [PMID: 34419147 DOI: 10.1186/s40168-021-01110-0] [Reference Citation Analysis]
|
| 195 |
Park SY, Faraci G, Nanda S, Ter-Saakyan S, Love TMT, Mack WJ, Dubé MP, Lee HY. Gut microbiome in people living with HIV is associated with impaired thiamine and folate syntheses. Microb Pathog 2021;160:105209. [PMID: 34563611 DOI: 10.1016/j.micpath.2021.105209] [Reference Citation Analysis]
|
| 196 |
Allaband C, McDonald D, Vázquez-Baeza Y, Minich JJ, Tripathi A, Brenner DA, Loomba R, Smarr L, Sandborn WJ, Schnabl B, Dorrestein P, Zarrinpar A, Knight R. Microbiome 101: Studying, Analyzing, and Interpreting Gut Microbiome Data for Clinicians. Clin Gastroenterol Hepatol 2019;17:218-30. [PMID: 30240894 DOI: 10.1016/j.cgh.2018.09.017] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 18.8] [Reference Citation Analysis]
|
| 197 |
Zhao M, Jiang Z, Cai H, Li Y, Mo Q, Deng L, Zhong H, Liu T, Zhang H, Kang JX, Feng F. Modulation of the Gut Microbiota during High-Dose Glycerol Monolaurate-Mediated Amelioration of Obesity in Mice Fed a High-Fat Diet. mBio 2020;11:e00190-20. [PMID: 32265324 DOI: 10.1128/mBio.00190-20] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 198 |
Kriss M, Verna EC, Rosen HR, Lozupone CA. Functional Microbiomics in Liver Transplantation: Identifying Novel Targets for Improving Allograft Outcomes. Transplantation 2019;103:668-78. [PMID: 30507741 DOI: 10.1097/TP.0000000000002568] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 199 |
Xia F, Xiang S, Chen Z, Song L, Li Y, Liao Z, Ge B, Zhou B. The probiotic effects of AB23A on high-fat-diet-induced non-alcoholic fatty liver disease in mice may be associated with suppressing the serum levels of lipopolysaccharides and branched-chain amino acids. Arch Biochem Biophys 2021;714:109080. [PMID: 34742934 DOI: 10.1016/j.abb.2021.109080] [Reference Citation Analysis]
|
| 200 |
Masoodi M, Gastaldelli A, Hyötyläinen T, Arretxe E, Alonso C, Gaggini M, Brosnan J, Anstee QM, Millet O, Ortiz P, Mato JM, Dufour JF, Orešič M. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34508238 DOI: 10.1038/s41575-021-00502-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 201 |
Kemas AM, Youhanna S, Lauschke VM. Non-alcoholic fatty liver disease - opportunities for personalized treatment and drug development. Expert Review of Precision Medicine and Drug Development 2022;7:39-49. [DOI: 10.1080/23808993.2022.2053285] [Reference Citation Analysis]
|
| 202 |
Aoki R, Onuki M, Hattori K, Ito M, Yamada T, Kamikado K, Kim YG, Nakamoto N, Kimura I, Clarke JM, Kanai T, Hase K. Commensal microbe-derived acetate suppresses NAFLD/NASH development via hepatic FFAR2 signalling in mice. Microbiome 2021;9:188. [PMID: 34530928 DOI: 10.1186/s40168-021-01125-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 203 |
Caussy C, Loomba R. Gut microbiome, microbial metabolites and the development of NAFLD. Nat Rev Gastroenterol Hepatol 2018;15:719-20. [PMID: 30158571 DOI: 10.1038/s41575-018-0058-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 204 |
Plichta DR, Graham DB, Subramanian S, Xavier RJ. Therapeutic Opportunities in Inflammatory Bowel Disease: Mechanistic Dissection of Host-Microbiome Relationships. Cell. 2019;178:1041-1056. [PMID: 31442399 DOI: 10.1016/j.cell.2019.07.045] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 30.5] [Reference Citation Analysis]
|
| 205 |
Zhang Q, Guo W, Chen G, Qian M, Han J, Lv X, Chen L, Rao P, Ai L, Ni L. Pediococcus acidilactici FZU106 alleviates high-fat diet-induced lipid metabolism disorder in association with the modulation of intestinal microbiota in hyperlipidemic rats. Current Research in Food Science 2022;5:775-88. [DOI: 10.1016/j.crfs.2022.04.009] [Reference Citation Analysis]
|
| 206 |
Mancin L, Rollo I, Mota JF, Piccini F, Carletti M, Susto GA, Valle G, Paoli A. Optimizing Microbiota Profiles for Athletes. Exerc Sport Sci Rev. 2021;49:42-49. [PMID: 33044333 DOI: 10.1249/jes.0000000000000236] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 207 |
Chen Z, Xie Y, Zhou F, Zhang B, Wu J, Yang L, Xu S, Stedtfeld R, Chen Q, Liu J, Zhang X, Xu H, Ren J. Featured Gut Microbiomes Associated With the Progression of Chronic Hepatitis B Disease. Front Microbiol 2020;11:383. [PMID: 32265857 DOI: 10.3389/fmicb.2020.00383] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 208 |
Abdul Rahim MBH, Chilloux J, Martinez-Gili L, Neves AL, Myridakis A, Gooderham N, Dumas ME. Diet-induced metabolic changes of the human gut microbiome: importance of short-chain fatty acids, methylamines and indoles. Acta Diabetol 2019;56:493-500. [PMID: 30903435 DOI: 10.1007/s00592-019-01312-x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 11.7] [Reference Citation Analysis]
|
| 209 |
Wang PX, Deng XR, Zhang CH, Yuan HJ. Gut microbiota and metabolic syndrome. Chin Med J (Engl). 2020;133:808-816. [PMID: 32106124 DOI: 10.1097/cm9.0000000000000696] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 210 |
Pomié C, Servant F, Garidou L, Azalbert V, Waget A, Klopp P, Garret C, Charpentier J, Briand F, Sulpice T, Lelouvier B, Douin-Echinard V, Burcelin R. CX3CR1 regulates gut microbiota and metabolism. A risk factor of type 2 diabetes. Acta Diabetol 2021;58:1035-49. [PMID: 33754166 DOI: 10.1007/s00592-021-01682-1] [Reference Citation Analysis]
|
| 211 |
Wang K, Liang X, Pang Y, Jiang C. The Role of Gut Microbiota in Host Lipid Metabolism: An Eye on Causation and Connection. Small Methods 2020;4:1900604. [DOI: 10.1002/smtd.201900604] [Reference Citation Analysis]
|
| 212 |
Arnoriaga-Rodríguez M, Fernández-Real JM. Microbiota impacts on chronic inflammation and metabolic syndrome - related cognitive dysfunction. Rev Endocr Metab Disord 2019;20:473-80. [PMID: 31884557 DOI: 10.1007/s11154-019-09537-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 213 |
Tan H, Nie S. Functional hydrocolloids, gut microbiota and health: picking food additives for personalized nutrition. FEMS Microbiol Rev 2021:fuaa065. [PMID: 33512498 DOI: 10.1093/femsre/fuaa065] [Reference Citation Analysis]
|
| 214 |
Mussap M, Noto A, Piras C, Atzori L, Fanos V. Slotting metabolomics into routine precision medicine. Expert Review of Precision Medicine and Drug Development 2021;6:173-87. [DOI: 10.1080/23808993.2021.1911639] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 215 |
Smith L, Villaret-Cazadamont J, Claus SP, Canlet C, Guillou H, Cabaton NJ, Ellero-Simatos S. Important Considerations for Sample Collection in Metabolomics Studies with a Special Focus on Applications to Liver Functions. Metabolites 2020;10:E104. [PMID: 32178364 DOI: 10.3390/metabo10030104] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 216 |
Pötgens SA, Thibaut MM, Joudiou N, Sboarina M, Neyrinck AM, Cani PD, Claus SP, Delzenne NM, Bindels LB. Multi-compartment metabolomics and metagenomics reveal major hepatic and intestinal disturbances in cancer cachectic mice. J Cachexia Sarcopenia Muscle 2021;12:456-75. [PMID: 33599103 DOI: 10.1002/jcsm.12684] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 217 |
Sookoian S, Pirola CJ. Liver tissue microbiota in nonalcoholic liver disease: a change in the paradigm of host-bacterial interactions. Hepatobiliary Surg Nutr 2021;10:337-49. [PMID: 34159161 DOI: 10.21037/hbsn-20-270] [Reference Citation Analysis]
|
| 218 |
Li M, Xu J, Zhang Y, Chu S, Sun S, Huo Y, Zhao J, Hu X, Wan C, Li L. Comparative analysis of fecal metabolite profiles in HFD-induced obese mice after oral administration of huangjinya green tea extract. Food and Chemical Toxicology 2020;145:111744. [DOI: 10.1016/j.fct.2020.111744] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 219 |
Adolph TE, Effenberger M, Tilg H. How our understanding of the microbiome has changed the way we look at liver diseases. Biomark Med 2018;12:1203-6. [PMID: 30444134 DOI: 10.2217/bmm-2018-0266] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 220 |
Ahmadi S, Wang S, Nagpal R, Wang B, Jain S, Razazan A, Mishra SP, Zhu X, Wang Z, Kavanagh K, Yadav H. A human-origin probiotic cocktail ameliorates aging-related leaky gut and inflammation via modulating the microbiota/taurine/tight junction axis. JCI Insight 2020;5:132055. [PMID: 32302292 DOI: 10.1172/jci.insight.132055] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 12.5] [Reference Citation Analysis]
|
| 221 |
Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 2021;69:1691-705. [DOI: 10.1136/gutjnl-2020-320622] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 26.5] [Reference Citation Analysis]
|
| 222 |
Ezzaidi N, Zhang X, Coker OO, Yu J. New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer. Cancer Lett 2019;459:186-91. [PMID: 31185249 DOI: 10.1016/j.canlet.2019.114425] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 223 |
Younes R, Bugianesi E. A spotlight on pathogenesis, interactions and novel therapeutic options in NAFLD. Nat Rev Gastroenterol Hepatol 2019;16:80-2. [PMID: 30559444 DOI: 10.1038/s41575-018-0094-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 224 |
Long X, Liu D, Gao Q, Ni J, Qian L, Ni Y, Fang Q, Jia W, Li H. Bifidobacterium adolescentis Alleviates Liver Steatosis and Steatohepatitis by Increasing Fibroblast Growth Factor 21 Sensitivity. Front Endocrinol (Lausanne) 2021;12:773340. [PMID: 35035378 DOI: 10.3389/fendo.2021.773340] [Reference Citation Analysis]
|
| 225 |
Clarke G, Sandhu KV, Griffin BT, Dinan TG, Cryan JF, Hyland NP, France CP. Gut Reactions: Breaking Down Xenobiotic–Microbiome Interactions. Pharmacol Rev 2019;71:198-224. [DOI: 10.1124/pr.118.015768] [Cited by in Crossref: 101] [Cited by in F6Publishing: 85] [Article Influence: 33.7] [Reference Citation Analysis]
|
| 226 |
Rom O, Liu Y, Liu Z, Zhao Y, Wu J, Ghrayeb A, Villacorta L, Fan Y, Chang L, Wang L, Liu C, Yang D, Song J, Rech JC, Guo Y, Wang H, Zhao G, Liang W, Koike Y, Lu H, Koike T, Hayek T, Pennathur S, Xi C, Wen B, Sun D, Garcia-Barrio MT, Aviram M, Gottlieb E, Mor I, Liu W, Zhang J, Chen YE. Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome. Sci Transl Med 2020;12:eaaz2841. [PMID: 33268508 DOI: 10.1126/scitranslmed.aaz2841] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 227 |
Bauer KC, Huus KE, Brown EM, Bozorgmehr T, Petersen C, Cirstea MS, Woodward SE, McCoy J, Hun J, Pamplona R, Ayala V, Finlay BB. Dietary Intervention Reverses Fatty Liver and Altered Gut Microbiota during Early-Life Undernutrition. mSystems 2020;5:e00499-20. [PMID: 32900869 DOI: 10.1128/mSystems.00499-20] [Reference Citation Analysis]
|
| 228 |
Muzurović E, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism 2021;119:154770. [PMID: 33864798 DOI: 10.1016/j.metabol.2021.154770] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 229 |
Lin J, Yang Q, Guo J, Li M, Hao Z, He J, Li J. Gut Microbiome Alterations and Hepatic Metabolic Flexibility in the Gansu Zokor, Eospalax cansus: Adaptation to Hypoxic Niches. Front Cardiovasc Med 2022;9:814076. [DOI: 10.3389/fcvm.2022.814076] [Reference Citation Analysis]
|
| 230 |
Chen YH, Wu WK, Wu MS. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review. Int J Mol Sci 2020;21:E5999. [PMID: 32825440 DOI: 10.3390/ijms21175999] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 231 |
Fougerat A, Montagner A, Loiseau N, Guillou H, Wahli W. Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease. Cells 2020;9:E1638. [PMID: 32650421 DOI: 10.3390/cells9071638] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 232 |
Mehal WZ, Loomba R. The Intestinal Microbiome, Plasma Metabolome, and Liver Transcriptome: A Conspiracy Driving Hepatic Steatosis. Hepatology 2019;70:741-4. [PMID: 30779368 DOI: 10.1002/hep.30577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 233 |
Jian C, Luukkonen P, Sädevirta S, Yki-Järvinen H, Salonen A. Impact of short-term overfeeding of saturated or unsaturated fat or sugars on the gut microbiota in relation to liver fat in obese and overweight adults. Clin Nutr 2021;40:207-16. [PMID: 32536582 DOI: 10.1016/j.clnu.2020.05.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 234 |
Becattini S, Sorbara MT, Kim SG, Littmann EL, Dong Q, Walsh G, Wright R, Amoretti L, Fontana E, Hohl TM, Pamer EG. Rapid transcriptional and metabolic adaptation of intestinal microbes to host immune activation. Cell Host Microbe 2021;29:378-393.e5. [PMID: 33539766 DOI: 10.1016/j.chom.2021.01.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
|
